PMC Articles for PubChem Compound (Select 57379345) - PMC

Result Filters

Links from PubChem Compound

Items: 1 to 20 of 113

<< First< Prev

Page of 6

Select item 112634781.

Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC

Konstantinos Arnaoutakis, Yin Wan, Jennifer Elliott, Matt Young, Yu Yin, Konstantinos Leventakos, Huamao M. Lin, Anastasios Dimou

Adv Ther. 2024; 41(8): 3217–3231. Published online 2024 Jun 25. doi: 10.1007/s12325-024-02899-6

PMCID:: PMC11263478

Abstract Article PDF–1.2M

Select item 109107542.

CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles

Marc Terrones, Christophe Deben, Felicia Rodrigues-Fortes, Anne Schepers, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer

J Transl Med. 2024; 22: 234. Published online 2024 Mar 3. doi: 10.1186/s12967-024-04988-0

PMCID:: PMC10910754

Abstract Article PDF–5.1M

Select item 108810893.

Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India

Dharna Gupta, Nidhi Gupta, Navneet Singh, Shankar Prinja

JCO Glob Oncol. 2024; 10: e2300260. Published online 2024 Feb 15. doi: 10.1200/GO.23.00260

PMCID:: PMC10881089

Abstract Article PDF–648K

Select item 108515464.

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang

BMC Cancer. 2024; 24: 186. Published online 2024 Feb 8. doi: 10.1186/s12885-024-11916-4

PMCID:: PMC10851546

Abstract Article PDF–3.7M

Select item 106628745.

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients

Huixian Zhang, Xingya Li, Ziheng Zhang, Siyuan Huang, Qianqian Guo, Ningning Yan

Medicine (Baltimore) 2023 Jul 21; 102(29): e33543. Published online 2023 Jul 21. doi: 10.1097/MD.0000000000033543

PMCID:: PMC10662874

Abstract Article PDF–519K

Select item 106094516.

Three Innovative Green and High-Throughput Microwell Spectrophotometric Methods for the Quantitation of Ceritinib, a Potent Drug for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: An Application to the Analysis of Capsules and Drug Uniformity Testing

Reem M. Abuhejail, Nourah Z. Alzoman, Ibrahim A. Darwish

Molecules. 2023 Oct; 28(20): 7054. Published online 2023 Oct 12. doi: 10.3390/molecules28207054

PMCID:: PMC10609451

Abstract Article PDF–1.5M

Select item 106080397.

Development of Two Novel One-Step and Green Microwell Spectrophotometric Methods for High-Throughput Determination of Ceritinib, a Potent Drug for Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Reem M. Abuhejail, Nourah Z. Alzoman, Ibrahim A. Darwish

Medicina (Kaunas) 2023 Oct; 59(10): 1813. Published online 2023 Oct 12. doi: 10.3390/medicina59101813

PMCID:: PMC10608039

Abstract Article PDF–4.1M

Select item 104698078.

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer

Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang

Cancer Med. 2023 Aug; 12(15): 15983–15997. Published online 2023 Jun 19. doi: 10.1002/cam4.6241

PMCID:: PMC10469807

Abstract Article PDF–3.8M

Select item 101862669.

罕见COX7A2L-ALK融合突变晚期肺腺癌1例病例报告并文献复习

YUAN Jiao, PAN Ruili, ZHONG Wei, WANG Mengzhao

Zhongguo Fei Ai Za Zhi. 2023 Apr 20; 26(4): 319–324. Chinese. doi: 10.3779/j.issn.1009-3419.2023.102.15

PMCID:: PMC10186266

Abstract Article PDF–2.2M

Select item 1015086710.

Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer

Qian Shen, Qiqi Gao, Jianying Zhou

Chin Med J (Engl) 2023 Apr 5; 136(7): 851–853. Published online 2023 Mar 14. doi: 10.1097/CM9.0000000000002403

PMCID:: PMC10150867

Article PDF–1.4M

Select item 1012223711.

Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells

Alyaksandr V. Nikitski, Vincenzo Condello, Saurabh S. Divakaran, Yuri E. Nikiforov

Thyroid. April 2023; 33(4): 464–473. Published online 2023 Apr 10. doi: 10.1089/thy.2022.0533

PMCID:: PMC10122237

Abstract Article PDF–1.7M

Select item 1004623412.

Tyrosine Kinase Inhibitors Target B Lymphocytes

Nikki Lyn Esnardo Upfold, Pavlo Petakh, Aleksandr Kamyshnyi, Valentyn Oksenych

Biomolecules. 2023 Mar; 13(3): 438. Published online 2023 Feb 25. doi: 10.3390/biom13030438

PMCID:: PMC10046234

Abstract Article PDF–1.2M

Select item 987333613.

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater

Cancer Res Treat. 2023 Jan; 55(1): 83–93. Published online 2022 Mar 25. doi: 10.4143/crt.2021.1571

PMCID:: PMC9873336

Abstract Article PDF–1.3M

Select item 974198214.

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence

Yurong Wang, Shujing Shen, Peizhu Hu, Di Geng, Ruipan Zheng, Xingya Li

Cancer Med. 2022 Dec; 11(23): 4491–4500. Published online 2022 May 26. doi: 10.1002/cam4.4834

PMCID:: PMC9741982

Abstract Article PDF–1.9M

Select item 967928115.

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation

Wenxin He, Xiankun Cao, Keyu Kong, Kewei Rong, Shuai Han, An Qin

Front Endocrinol (Lausanne) 2022; 13: 939959. Published online 2022 Nov 8. doi: 10.3389/fendo.2022.939959

PMCID:: PMC9679281

Abstract Article PDF–4.7M

Select item 963331416.

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer

Takuya Sakashita, Noriko Yanagitani, Sumie Koike, Siew‐Kee Low, Satoshi Takagi, Satoko Baba, Kengo Takeuchi, Makoto Nishio, Naoya Fujita, Ryohei Katayama

Cancer Sci. 2022 Nov; 113(11): 3888–3900. Published online 2022 Sep 11. doi: 10.1111/cas.15529

PMCID:: PMC9633314

Abstract Article PDF–12M

Select item 963235617.

Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report

Christiane Wiedemann, Daniel Kazdal, Jelena Cvetkovic, Julia Kunz, David Fisch, Martina Kirchner, Mark Kriegsmann, Holger Sültmann, Claus-Peter Heussel, Helge Bischoff, Michael Thomas, Albrecht Stenzinger, Petros Christopoulos

Cold Spring Harb Mol Case Stud. 2022 Oct; 8(6): a006234. doi: 10.1101/mcs.a006234

PMCID:: PMC9632356

Abstract Article PDF–9.8M

Select item 957910818.

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models

Janina Fischer-Mertens, Felix Otte, Andrea Roderwieser, Carolina Rosswog, Yvonne Kahlert, Lisa Werr, Anna-Maria Hellmann, Maya Berding, Bill Chiu, Christoph Bartenhagen, Matthias Fischer

Cell Oncol (Dordr) 2022; 45(5): 991–1003. Published online 2022 Aug 12. doi: 10.1007/s13402-022-00702-8